Form 4: Cogent Biosciences Director Acquires Stock Options, Disclaims Personal Beneficial Ownership

Christopher W. Cain, a Director at Cogent Biosciences, Inc., was granted 44,700 stock options with an exercise price of $5.64, which he holds for the benefit of Fairmount Funds Management LLC.

Summary

• Christopher W. Cain, a Director of Cogent Biosciences, Inc. (COGT), acquired 44,700 stock options on June 4, 2025.
• The options have an exercise price of $5.64 per share and are set to expire on June 4, 2035.
• These stock options will vest in full upon the earlier of the first anniversary of the grant date (June 4, 2026) or the date of the 2026 Annual Meeting of Stockholders.
• Mr. Cain holds these options for one or more investment vehicles managed by Fairmount Funds Management LLC and is obligated to turn over any net cash or stock received to the Adviser for the benefit of such Fairmount Fund.
• Consequently, Mr. Cain disclaims beneficial ownership of the option and the underlying common stock.

Sentiment

Score: 6

Explanation: The filing is a routine disclosure of an insider stock option grant. While the grant itself is a positive for incentive alignment, the disclaimer of personal beneficial ownership by the director slightly dampens the direct personal incentive aspect. It's a neutral to slightly positive event, as it indicates continued involvement and alignment, albeit indirectly.

Positives

• The grant of stock options to a director aligns management incentives with shareholder value, even if the direct personal beneficial ownership is disclaimed.
• The options have a long expiration date of 10 years, providing ample time for potential value realization if the company's stock price appreciates.

Negatives

• The director disclaims personal beneficial ownership of the options, indicating they are held for an investment vehicle rather than for his direct personal financial benefit, which might reduce the direct personal incentive alignment.

Risks

• The value of the stock options is entirely dependent on the future stock price of Cogent Biosciences exceeding the exercise price of $5.64.
• The full benefit of the options is subject to a vesting schedule, meaning they are not immediately exercisable in full and require the passage of time or a specific event (2026 Annual Meeting).

Future Outlook

The grant of stock options with a 10-year expiration period suggests a long-term view on the company's potential stock price appreciation. The vesting schedule indicates that the full benefit of these options will be realized no later than the 2026 Annual Meeting of Stockholders.

Management Comments

• Christopher W. Cain disclaims beneficial ownership of the option and underlying common stock, stating he holds them for one or more investment vehicles managed by Fairmount Funds Management LLC and is obligated to turn over any net cash or stock received for the benefit of such Fairmount Fund.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology and pharmaceutical industries, aiming to align the interests of insiders with long-term shareholder value. The specific terms, such as exercise price and vesting schedule, reflect the company's compensation philosophy and outlook.

Comparison to Industry Standards

• Granting stock options to directors is a standard practice in the biotech industry, similar to companies like Moderna or BioNTech, to incentivize long-term performance.
• A 10-year expiration period for stock options is typical for long-term incentive plans across various industries, including biotech, providing a substantial window for value creation.
• The vesting schedule (full vesting by 2026 Annual Meeting or one year) is a common accelerated vesting approach for director grants, often seen in smaller or growth-oriented biotech firms to ensure retention and immediate alignment.
• The disclaimer of beneficial ownership, where options are held for an investment vehicle, is less common for individual director grants but can occur when a director represents an institutional investor on the board, as seen with some private equity or venture capital representatives on public company boards.

Related Party Transactions

• Christopher W. Cain holds the 44,700 stock options for one or more investment vehicles managed by Fairmount Funds Management LLC.
• Mr. Cain is obligated to turn over any net cash or stock received from the option for the benefit of such Fairmount Fund.
• Mr. Cain disclaims beneficial ownership of the option and underlying common stock due to this arrangement.

Stakeholder Impact

• Shareholders: The grant of options aligns the interests of a director (and indirectly, Fairmount Funds Management LLC) with long-term shareholder value, as the options gain value only if the stock price increases.
• Management/Directors: Christopher W. Cain receives an equity incentive, though the direct personal financial benefit is transferred to Fairmount Funds.

Next Steps

• Monitoring of the vesting of the 44,700 stock options by June 4, 2026, or the 2026 Annual Meeting of Stockholders.
• Future Form 4 filings will report any exercise or disposition of these options.

Key Dates

Recommendation

Keywords

Cogent Biosciences, COGT, Stock Option, Form 4, Insider Transaction, Director Compensation, Beneficial Ownership, Fairmount Funds Management, Equity Grant